Bedrijfsoverzicht
Cronos Group Inc. is a cannabinoid company that actively engages in the cultivation, production, distribution, and marketing of cannabis products across Canada, Israel, and international markets. The firm operates within the Healthcare sector, specifically categorized under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on specialized pharmaceutical and botanical compounds rather than general consumer goods. The company's operational scale is defined by a market capitalization of $992.32M, an annual revenue of $146.59M, and an workforce consisting of 610 employees. These valuation and revenue figures indicate that Cronos Group Inc. holds a mid-cap position in the specialized cannabis manufacturing space, suggesting a business that has achieved significant scale in product offerings such as dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under brands like Spinach, Lord Jones, Lit, and Peace Natura, yet still operates with a market valuation that reflects the high-risk, high-growth nature of the industry.
Financiële gezondheid
The company reported a revenue of $146.59M over the trailing twelve months, yet recorded a net income of $-9,447,000 and an EBITDA of $-3,353,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, including cost of goods sold, selling, general, and administrative costs, significantly outweigh the gross profits generated from sales. This negative free cash flow of $-51,218,376 indicates that the company is currently burning cash to fund its expansion and operations, which impacts its immediate financial flexibility and ability to self-fund growth initiatives without external capital. Despite these negative earnings, the company maintains a robust cash position of $831.79M, which stands in stark contrast to its minimal debt load of $1.51M. This disparity is further highlighted by a debt-to-equity ratio of 0.13, suggesting that the balance sheet is highly conservative and leveraged to a negligible degree. Liquidity is exceptionally strong, evidenced by a current ratio of 19.59, which indicates that the company possesses ample current assets to cover its short-term liabilities many times over. However, the return metrics reveal the challenges of profitability; the return on equity stands at -0.3% and the return on assets is -0.9%, indicating that management has not yet generated positive returns on the capital invested in the business or the assets utilized to generate revenue.
Waarderingsbeoordeling
The valuation metrics present a complex picture for an unprofitable entity, with a trailing P/E ratio marked as N/A due to the lack of net income, while the forward P/E is listed at -64.50. The negative forward P/E implies that analysts or the market expects earnings to remain negative in the coming period, or that the current valuation is based on projected losses rather than established profitability. The price-to-book ratio of 0.90 suggests that the market values the company at roughly 90% of its net asset value, indicating no significant market premium over the book value of its equity. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 6.77 and an EV/EBITDA of -58.67, which suggest the market is pricing the stock based on its revenue generation capabilities and asset base rather than current earnings power. Regarding price momentum, the stock has traded within a 52-week range between a high of $3.43 and a low of $1.69. Without a specific current share price provided in the facts, the relative trading position cannot be calculated as a percentage, but the range demonstrates a wide volatility typical of the sector. The beta of 1.21 indicates that the stock's price volatility is 21% higher than the broader market, meaning it is expected to move more aggressively than the S&P 500 in response to market fluctuations.
Growth & Income
The company demonstrates aggressive expansion with a revenue growth rate of 47.0% year-over-year, while earnings growth is marked as N/A due to the lack of reported net income for the comparison period. Since there are no earnings to compare, the rapid revenue expansion implies that top-line growth is currently the primary driver of the business, while the bottom line has not yet caught up, likely due to the high cash burn mentioned in the financial health section. Cronos Group Inc. does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available earnings and cash reserves back into the business to fuel the cultivation and distribution efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by high revenue velocity and a complete absence of dividend income, positioning the stock as a speculative growth play dependent on future profitability to stabilize.